Paradoxical role of apoptosis in tumor progression

Journal of Cellular Biochemistry

Volumn 88, Issue 1, 2003, Pages 128-137

  Gurova, Katerina V ^a   Gudkov, Andrei V ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; Bcl 2; Genomic stability; p53; Tumor progression

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ANIMAL MODEL; APOPTOSIS; CELL DEATH; CELL PROLIFERATION; COLORECTAL TUMOR; EXPERIMENTAL NEOPLASM; LUNG TUMOR; MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSGENIC ANIMAL; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; DISEASE PROGRESSION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037216725     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10382     Document Type: Review

References (47)

1. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborn CK, Allred DC. 1998. Bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 82:1296-1302.
2. Binder C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W. 1995. Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann Oncol 6:1005-1010.
3. Castiglione F, Sarotto I, Fontana V, Destifanis M, Venturino A, Ferro S, Cardaropoli S, Orengo MA, Porcile G. 1999. Bcl-2, p53 and clinical outcome in series of 138 operable breast cancer patients. Anticancer Res 19:4555-4563.
4. De la Coste A, Mignon A, Fabre M, Gilbert E, Porteu A, Van Dyke T, Kahn A, Christine P. 1999. Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice. Cancer Res 59:5017-5022.
5. Deichman GI, Matveeva VA, Kashkina LM, Dyakova N, Uvarova E, Nikiforov M, Gudkov A. 1998. Cell transforming genes and tumor progression: In vivo-unified secondary phenotypic cell changes. Int J Cancer 75:277-283.
6. Diaz JI, Pow-Sang JM, Mora LB, Seign JD, Cantor AB, Dalton WS. 2000. Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer. Urol Oncol 5:149-154.
7. Eerola AK, Ruokolainen H, Soini Y, Raunio H, Paakko P. 1999. Accelerated apoptosis and low bcl-2 expression associated with neuroendocrine differentiation predict shortened survival in operated large cell carcinoma of the lung. Pathol Oncol Res 5:179-186.
8. Eguchi H, Suga K, Saji H, Toi M, Nakachi K, Hayashi SI. 2000. Different expression patterns of Bcl-2 family genes in breast cancer by estrogen receptor status with special reference to pro-apoptotic Bak gene. Cell Death Differ 7:439-446.
9. Evan GI, Vousden KH. 2001. Proliferation, cell cycle and apoptosis in cancer. Nature 411:342-348.
10. Furth PA, Bar-Peled U, Li M, Lewis A, Laucirica A, Jager R, Weiher H, Russel RG. 1999. Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model. Oncogene 18:6589-6596.
11. Graeber TG, Osmanian S, Jacks T, Housman DE, Koch CJ, Lowe S, Giaccia AJ. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379:88-91.
12. Gurova KV, Kwek SS, Koman IE, Kamarov AP, Kandel E, Nikiforov MA, Gudkov AV. 2002. Apoptosis inhibitor as a suppressor of tumor progression: Expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor. Cancer Biol Ther 1:39-44.
13. Haitek A, Posch B, El-Baz M, Mokhtar AA, Susani M, Ghoneim MA, Marberger M. 2001. Bilharzial related, organ confined, muscle invasive bladder cancer: Prognostic value of apoptotic markers, p53, E-cadherin, epidermal growth factor receptor and c-rebB-2. J Urol 165:1481-1487.
14. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. 1994. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54:2095-2097.
15. Hamilton A, Piccart M, 2000. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53, and BCL-2. Ann Onco 11:647-663.
16. Hotz MA, Bosq J, Zbaeren P, Reed J, Schwab G, Krajewski S, Brousset P, Borner MM. 1999. Spontaneous apoptosis and the expression of p53 and Bcl-2 family proteins in locally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 125:417-422.
17. Howard JC, Li Q, Chu W, Zochodne B, Kapoor M, Ung Y, Rosen K, Ben-David Y. 2001. Bcl-2 expression in F-MuLV-induced erythroleukemias: A role for the antiapoptotic action of Bcl-2 during tumor progression. Oncogene 20:2291-2300.
18. Huang DCS, O'Reilly LA, Strasser A, Cory S. 1997. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 16:4628-4638.
19. Inada T, Kikuyama S, Ichikawa A, Igarashi S, Ogata Y. 1998. Bcl-2 expression as a prognostic factor of survival of gastric carcinoma, Anticancer Res 18:2003-2010.
20. Joensuu H, Pylkkanen L, Toikkanen S. 1994. Bcl-2 protein expression and long term survival in breast cancer. Am J Pathol 145:1191-1198.
21. Johnstone RW, Ruefli AA, Lowe SW. 2002, Apoptosis: A link between cancer genetics and chemotherapy. Cell 108:153-164.
22. Kajiwara T, Tatkeuchi T, Ueki T, Moriyama N, Ueki K, Kakizoe T, Kawabe K. 1999. Effect of Bcl-2 overexpression in human prostate cancer cells in vitro and in vivo. Int J Urol 6:520-525.
23. Kandouz M, Siromachkova M, Jacob D, Chretien Market B, Therwath A, Gompel A. 1996. Antagonism between estradiol and progestin on Bcl-2 expression in breast cancer cell line. Int J Cancer 68:120-125.
24. Knudson CM, Johnson GM, Lin Y, Korsmeyer SJ. 2001. Bax accelerates tumorigenesis in p53-deficient mice. Cancer Res 61:659-655.
25. Kobayashi S, Iwase H, Ito Y, Yamashita H, Iwata H, Yamashita T, Ito K, Toyama T, Nakamura T, Masaoka A. 1997. Clinical significance ofbcl-2 gene expression in human breast cancer tissues. Breast Cancer Res Treat 42:173-181.
26. Koide N, Koike S, Adachi W, Amano J, Usuda N, Nagata T. 1997. Immunohystochemical expression of bcl-2 protein in squamous cell carcinoma of the esophagus. Surg Today 27:685-691.
27. Krajewska M, Moss SF, Krajevski S, Song K, Holt PR, Reed JC. 1996. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinoma. Cancer Res 56:2422-2427.
28. Kurabayashi A, Furihata M, Matsumoto M, Ohtsuki Y, Sasaguri S, Ogoshi S. 2001, Expression of Bax and apoptosis-related proteins in human esophageal squamous cell carcinoma including dysplasia. Mod Pathol 14:741-747.
29. Lazaris AC, Lenardi I, Kavantzas N, Kandiloros D, Adamapoulos G, Davaris P. 2000. Correlation of tumor markers p53, bcl-2 and cathepsin-D with clinicopathological features and desease-free survival in laringeal squamous cell carcinoma, Pathol Int 50:717-724.
30. Li L, Yan L, Wang Z, Liu Z, Wei Y, Huang G. 2000. Change of apoptotic status in human colorectal adenoma-carcinoma stages sequences and its correlation with carcinogenesis and prognosis. Clin Med J 113:886-888.
31. Liu HF, Liu WW, Fang DC, Men RP., 1998. Expression of bcl-2 protein in gastric carcinoma and its significance. World J Gastroenterol 4:228-230.
32. Megha T, Ferrari F, Benvenuto A, Bellan C, Lalinga AV, Lazzi S, Bartolommei S, Cevenini G, Leoncini L, Tosi P. 2002. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin. J Clin Pathol 55:461-466.
33. Saegusa M, Okayasu I. 1997. Bcl-2 is closely correlated with favorable prognosric factors and inversely associated with p53 protein accumulation in endometrial carcinomas: Immunohistochemical and poymerase chain reaction/loss of heterozygosity findings. J Cancer Res Clin Oncol 123:429-434.
34. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. 2002a. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1:289-298.
35. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW. 2002b. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109:335-346.
36. Shimizu S, Eguchi Y, Kamiike W, Itoh Y, Hasegawa J, Yamabe K, Otsuki Y, Matsuda H, Tsujimoto Y. 1996. Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by bcl-2 and bcl-X. Cancer Res 56:2161-2166.
37. Sjostrom J, Bergh J. 2001. How apoptosis is regulated, and what goes wrong in cancer. BMJ 322:1538-1539.
38. Takayama T, Nagao M, Sawada H, Yamada Y, Emoto K, Fujimoto H, Ueno M, Hirao S, Nakajima Y. 2001. Bcl-X expression in esophageal squamous cell carcinoma: Association with tumor progression and prognosis. J Surg Oncol 78:116-123.
39. Tanji N, Yokoyama M, Sugamoto T, Takeuchi M, Terada N. 1998. Apoptosis in prostatic adenocarcinomas: A study of relationship to Ki-67 and Bcl-2 protein expression. Anticancer Res 18:1111-1116.
40. Teixeira C, Reed JC, Pratt MA. 1995. Estrogen promotes chemoterapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55:3902-3907.
41. Tete S, Pappalardo S, Fioroni M, Salini L, Imperatrice AM, Perfetti G. 1999. Bcl-2, p53, Ki67 and apoptotic index in cancerous and precancerous lesions of the oral mucosa. Minerva Stomatol 48:419-425.
42. Tjalma W, De Cuyper E, Weyler J, Van Marck E, De Pooter C, Albertyn G, van Dam P. 1998. Expression of bcl-2 in invasive and in situ carcinoma of the uterine cervix. Am J Obstet Gynecol 178(1 Pt 1):113-117.
43. Vail M, Pierce RH, Fausto N. 2001. Bcl-2 delays and alters hepatic carcinogenesis induced by transforming growth factor? Cancer Res 61:594-601.
44. Vakkala M, Lahteenmaki K, Raunio H, Paakko P, Soini Y. 1999. Apoptosis during breast carcinoma progression. Clin Cancer Res 5:319-324.
45. Van Slooten HJ, van de Vijver MJ, van de Velde CJ, van Dierendonck JH. 1998. Loss of bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer 77:789-796.
46. Zhang GJ, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K, Tsuchiya A. 1998. Apoptotic index correleates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res 18:1989-1998.
47. Zornig M, Hueber A, Baum W, Evan G. 2001. Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 1551:F1-F37.